The Clinical Trials Office (CTO) provides administrative and educational support for clinical, translational and population based studies for investigators of the NYU Cancer Institute (NYUCI). It also provides the research staff to carry out the objectives of the study. It serves as the main coordinating center for protocol development, regulatory and compliance guidance, administrative submissions, data collection and management, data analysis, and quality assurance. It also serves as the administrative interface to other clinical research organizations at the NYU Langone Medical Center (NYULMC). The goals of this resource are to: facilitate clinical trials by providing a framework for trial development, submission for institutional approval (PRMS and IRB), budgeting and conduct of clinical trials;ensure appropriate standards of clinical trial conduct across the institution and strategic alliances by maintaining data management, regulatory, and nursing guidelines as well as auditing conduct of trials;provide educational programs and mentorship for the CTO staff, fellows, and clinical investigators;and promote interdisciplinary collaboration and venues for translating research findings to the clinical arena. Since the last review, a new medical director was appointed and a number of senior level positions were established and subsequently filled. This resulted in streamlining processes and the development of new metrics to better assess resource allocations. Since the last review accruals increased at the main institution and at Bellevue Hospital Center. Currently, the CTO supervises 49 research staff and manages 151 open protocols. The CTO continues to expand and improve its function to serve as the central coordinating center for the clinical research enterprise at the NYUCI.

Public Health Relevance

;The CTO works as a centralized coordinating center for all aspects of conducting clinical research at NYUCI. The structure provided by the CTO assists to move novel therapeutic agents from bench to bedside and provide an avenue for access to clinical trials all patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-33
Application #
8436453
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-03-01
Project End
2018-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
33
Fiscal Year
2013
Total Cost
$134,521
Indirect Cost
$55,157
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Wadghiri, Youssef Z; Hoang, Dung Minh; Leporati, Anita et al. (2018) High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. Sci Rep 8:7687
Khodadadi-Jamayran, Alireza; Akgol-Oksuz, Betul; Afanasyeva, Yelena et al. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9:12868-12878
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:

Showing the most recent 10 out of 1170 publications